The National Medical Products Administration has accepted the supplemental new drug application seeking the approval of toripalimab in combination with nab-paclitaxel in patients with untreated metastatic or recurrent triple-negative breast cancer and a PD-L1 combined positive score of at least 1.
VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ USA News Group - So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last
/PRNewswire/ USA News Group - So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last.
Zai Lab Ltd (via Public) / Zai Lab Announces NDA Acceptance of publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.